Skye Bioscience Shareholders Who Lost Money Encouraged to Join Class Action

Notice to Shareholders of Skye Bioscience, Inc.

On December 8, 2025, The Gross Law Firm released an important announcement aimed at shareholders of Skye Bioscience, Inc. (NASDAQ: SKYE). This notice serves as a call for those who have suffered financial losses to consider joining a class action lawsuit. Shareholders who purchased SKYE shares between November 4, 2024, and October 3, 2025, are particularly encouraged to reach out to the firm for further information regarding the possibility of being appointed as lead plaintiffs.

Background Information

The class action comes on the heels of serious allegations concerning the company’s lead product candidate, nimacimab. According to the claims, the defendants made materially false and/or misleading statements during the class period. They purportedly failed to reveal that nimacimab was not as effective as previously projected, thereby inflating its clinical, regulatory, and commercial prospects. As a result of these misstatements, investors were misled, ultimately leading to significant financial losses when the truth came to light.

Important Dates

For those considering joining the class action, the deadline to register is January 16, 2026. It’s crucial for affected shareholders not to delay in submitting their information, as participation is imperative for seeking recovery. Joining the class action does not require individuals to take on the responsibilities of being lead plaintiffs, although that option remains available for willing participants.

Next Steps for Interested Shareholders

Once a shareholder registers, they will be enrolled in a portfolio monitoring software. This service will provide updates on the case and allow participants to stay informed on various developments throughout its lifecycle. The registration process is simple, and there are no financial obligations or costs associated with participation in the class action.

Why Choose The Gross Law Firm?

The Gross Law Firm has established a strong reputation as a national class action law firm committed to safeguarding the rights of investors who have faced losses due to corporate misconduct. Their mission includes promoting accountability for companies that engage in deceitful practices. Investors who fall victim to misleading statements or omissions of significant information can find solace in the firm’s commitment to pursuing justice and recovery on their behalf.

With an experienced team dedicated to ensuring responsible business practices, The Gross Law Firm seeks to provide support to investors facing challenges due to corporate fraud and misconduct. By taking action through this class action lawsuit, shareholders stand a better chance of recovering their losses from Skye Bioscience.

Contact Information

If you believe you qualify and would like to learn more about the class action, please do not hesitate to reach out:

The Gross Law Firm
15 West 38th Street, 12th Floor
New York, NY, 10018
Email: [email protected]
Phone: (646) 453-8903

In conclusion, shareholders of Skye Bioscience should act promptly to safeguard their rights and seek potential financial recovery through the upcoming class action. The Gross Law Firm is here to assist you on this journey toward justice and accountability.